H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Personalis to $9 from $7.50 and keeps a Buy rating on the shares. The firm says the Tempus investment accelerates NeXT Personal commercialization. The cash infusion not only helps to extend Personalis’ cash runway, but also serves as another validation of NeXT Personal’s market potential, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL: